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The immune system is vital for detecting and evading endogenous and exogenous threats to the body.
Failure to regulate this homeostasis leads to autoimmunity, which is often associated with
malfunctioning T cell signaling. Several medications are available to suppress over-reactive T
lymphocytes, but many of the currently marketed drugs produce severe and life-threatening side-effects.
Ribosomally synthesized peptides are gaining recognition from the pharmaceutical industry for their
enhanced selectivity and decreased toxicity compared with small molecules; in particular, circular
peptides exhibit remarkable stability and increased oral administration properties. For example, plant
cyclotides effectively inhibit T lymphocyte proliferation. They are composed of a head-to-tail cyclized
backbone and a cystine-knot motif, which confers them with remarkable stability, thus making them
attractive pharmaceutical tools.Introduction
The immune system is responsible for detecting and eliminating
foreign pathogens and tumor cells, but avoiding self-recognition.
Therefore, tolerance mechanisms are continuously under surveil-
lance to retain this homeostasis. If these immunological tools are
over-reactive it can lead to autoimmunity, targeting healthy host
cells and organs as well as exogenous and endogenous threats.
About 5% of the population in Western countries develops an
autoimmune disease during life, and these numbers are constantly
increasing [1]. The causes of autoimmunity are still ill-defined, but
it is known that there are many parameters involved, such as
gender, genetic background, environmental factors and, impor-
tantly, malfunctioning lymphocyte development [2]. However,
autoimmunity is not only a congenital disease; following an
infection, certain bacterial proteins can elicit an ‘unwanted’
immune response. Conversely, there is a link between the
decreased appearance of bacterial and parasitic infectious diseases
and an increase of allergic reactions, supported by the so-calledCorresponding author:. Gruber, C.W. (christian.w.gruber@meduniwien.ac.at)
1 These authors contributed equally.
1359-6446/06  2013 The Authors. Published by Elsevier Ltd.  http:/Open access under CC BY-NC-ND license.hygiene hypothesis [3]. Autoimmune diseases can be broadly
classified as organ-specific (e.g. multiple sclerosis) or as systemic
(e.g. systemic lupus erythematosus). On a molecular level, auto-
reactive T cells play an important part in disease development and
progression [4], and therefore it is a fundamental necessity to take
T cell associated pathways into consideration, especially interleu-
kin 2 (IL2) signaling. Gene expression of this T cell growth factor
cytokine is induced by the transcription factors NFAT, NFkB or AP-
1. IL2 then acts in an autocrine fashion on its own high-affinity
cell surface receptor (IL2R) to promote cell proliferation, cell
growth and/or inhibition of apoptosis inter alia via mTOR [5,6]
(for immunological glossary of terms, see Box 1).
Immunosuppressive pharmaceuticals
Various signaling pathways and associated canonical messenger
molecules, such as IL2 signaling molecules, offer targets for drug
discovery for the treatment of an over-reactive immune response
as is the case in autoimmune diseases, allergic reactions and
following organ transplantation. Many immunosuppressive
agents have already been used in the clinic, demonstrating efficacy
while displaying different modes-of-action. Some of these phar-
maceuticals target specific kinases and phosphatases, interfere
with gene expression, modify DNA via alkylation or inhibit purine
or pyrimidine synthesis to block the cell cycle [7]./dx.doi.org/10.1016/j.drudis.2013.12.002 www.drugdiscoverytoday.com 645
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BOX 1
Immunological glossary
Abbreviation Term and/or explanation
CD Cluster of differentiation
CRAC Ca2+-release-activated channels
IKCa1 Intermediate conductance calcium-activated
potassium channel protein 4 (KCNN4)
Kv1.3 Potassium voltage-gated channel, shaker-related
subfamily, member 3 (KCNA3)
IP3 Inositol-1,4,5-triphosphate
IP3R Intramolecular inositol-1,4,5-triphosphate
Ca2+-release channel
NFAT Nuclear factor of activated T cells
NFkB Nuclear factor ‘k-light-chain-enhancer’ of
activated B cells
AP-1 Activator protein 1 (dimerization of Fos and Jun)
IL2 Interleukin-2
IL2R High affinity CD25+ interleukin-2 receptor
mTOR Mammalian target of rapamycin
IFNg Interferon g
TGFb Transforming growth factor b
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torically one of the oldest are the glucocorticoids. They restrict and
inhibit the synthesis and secretion of inflammatory cytokines and
support the activation of anti-inflammatory signaling cascades.
The best-known member of this class of compounds is cortisone,
which interacts with and inhibits, for example, NFkB-dependent
signaling, resulting in reduced expression of inflammatory cyto-
kines such as tumor necrosis factor (TNF)a or IL1. Besides, gluco-
corticoid treatment affects many non-immune related signaling
pathways; it interferes in gluconeogenesis, lipolysis, protein cat-
abolism and sodium retention. Consequently, the list of side-
effects is long, ranging from Cushing’s syndrome, hyperglycemia,
myopathia, skin atrophy, osteoporosis, hypertonia, weight gain
and immunodeficiency [8].
Vitamin D, a fat-soluble secosteroid, has recently been success-
fully implemented in immunotherapy although it is not a classical
anti-inflammatory agent. The physiologically active form of vita-
min D [i.e. calcitriol (1,25-dihydroxycholecalciferol)] shows
immunosuppressive properties. Activated T and B cells express
the vitamin D receptor on their surface, which can be used to
downregulate IL2 signaling. Supplementation therapy of vitamin
D has already demonstrated protective effects in the treatment of
multiple sclerosis [9]. Other immunosuppressive agents interfere
with the cell cycle. For example, the enzyme inhibitors azathiopr-
ine, mycophenolate mofetil and methotrexate are non-peptide
drugs affecting proliferation by targeting and blocking purine and
pyrimidine synthesis [10].
The application of monoclonal antibodies (mAbs), which exhi-
bit high specificity towards their appropriate protein epitopes and
hence provide the opportunity to inhibit a target molecule and its
resulting effects selectively, is the subject of a tremendous amount
of research and constitutes an important branch in the field of
immunotherapies. The first mAb approved by the FDA in 1986 was
muromonab (Orthoclone1 OKT3) directed against human CD3
[11]. It was withdrawn from the market for therapeutic application
as a result of high toxicity in 2008, but it still has importance
in nonclinical applications [10,12]. Anti-TNF or -TNFR mAbs646 www.drugdiscoverytoday.com(e.g. infliximab, adalimumab or golimumab) are widely used in
the treatment of rheumatoid arthritis, Bechterew’s disease, psor-
iasis or inflammatory bowel diseases [13]. Blocking different
immunological cell surface molecules, such as CD52 (alemtuzu-
mab) [12], CD25 (basiliximab) [14] and CD20 (rituximab), is
important in the treatment of autoimmune diseases [15].
Together, mAbs account for over US$40 billion in pharmaceutical
sales, and anti-TNF antibodies or protein-based inhibitors remain
among the most important therapies for the treatment of many
autoimmune disorders [16]. Besides the great therapeutic success
of mAbs, adverse effects similar to immunodeficiencies or the
formation of anti-drug antibodies are a frequently occurring phe-
nomena [13,17]. Furthermore, the lack of homogeneous tissue
distribution, limited half-life and enormous production costs
decrease the attractiveness of this epitope-specific passive immu-
notherapy. In summary, all commonly used immunosuppressive
drugs demonstrated great success in the treatment of autoimmune
diseases. However, many of them cause unwanted and severe side-
effects in patients and therefore there is a high demand for less-
toxic immunosuppressive pharmaceuticals.
Immunosuppressive peptides
Bioactive peptides and, in particular, ribosomally synthesized
peptides often show reduction in cytotoxicity as compared with
small organic compounds – obviously as a result of their inherent
targeted molecular action [18–21]. However, it is important to
note that drug toxicity is a factor that is compound dependent and
there is no panacea that guides whether one compound will or will
not be toxic in humans. In the following section we would like to
provide an overview of natural peptides (i.e. non-ribosomally and
ribosomally synthesized ones) that have not been released on the
market yet, but that show promising immunosuppressive proper-
ties (Table 1).
Non-ribosomally synthesized peptides
Utilization of bioactivity screening led to the identification of a
plethora of novel and potentially immunosuppressive compounds
in micro- and marine-organisms [22]. Few examples of non-ribo-
somally synthesized peptides interfering in cytokine signaling are
cyclosporine A (CsA), sirolimus and tracrolimus. CsA (Fig. 1a), a
cyclic peptide of fungal origin (Tolypocladium inflatum), is widely
used in the treatment of autoimmune diseases and to prevent
allograft rejection of a transplanted organ. CsA antagonizes the
activity of calcineurin, a calcium-dependent serine–threonine
phosphatase, which dephosphorylates and activates the transcrip-
tion factor NFAT to stimulate expression of IL2. Therefore, the
dephosphorylation of NFAT is inhibited and consequently the IL2-
dependent T cell proliferation repressed. Besides, CsA interferes
additionally with p38 and JNK signaling cascades [10,23]. Owing
to multiple target pathways, the therapeutic potential of CsA is
limited, in particular during long-term treatment, because it has
several side-effects, such as hepatotoxicity, nephrotoxicity, neu-
rotoxicity and cytotoxicity [24].
FKBP-12 (FK506-binding protein) functions as a chaperone and
belongs, together with cyclophilin, to the family of immunophi-
lins. Tacrolimus (FK506), a macrolide lactone first isolated from
Streptomyces tsukubaensis interferes with calcineurin-dependent
IL2 signaling, by inhibiting FKBP-12 50-fold more potently than
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TABLE 1
Immunosuppressive peptides: molecular targets, side-effects and market status
Name Chemical class Origin Molecular target(s) Side-effects Market status Refs
Non-ribosomally synthesized peptides
Antamides Cyclic peptide,
cycloamanide
peptides
Amanita phalloides
spp. (fungus)
Inhibition of
mitochondrial
permeability
transition pores
Induces cell
necrosis
In vitro and in vivo
studies
[80,81]
Collutellin A Cyclic octapepide Colletotrichum
dematium (fungus)
Reduces IL2
production
Low cytotoxicity
reported
In vitro [20]
Cyclosporine A Cyclic undecapeptide Tolypocladium inflatum
(fungus)
Inhibition of
calcineurin by
complex with
cyclophilins
Hepatotoxicity,
nephrotoxicity,
neurotoxicity,
cytotoxicity
Released: CicloralW,
CiclosolW,
ImmunosporinW,
NeoimmunW,
SandimmunW, OptoralW
[23,25,82]
Didemnin A/B Cyclic depsipeptide Trididemnum solidum
(tunicate)
Blocks protein and
RNA synthesis, binds
to eEFA1 and PPT-1
Antiproliferative,
long-term
allograft survival
were not
achieved
In vivo studies (mice),
Phase II clinical trials
[22,28,29]
FK506 (tracrolimus)
Ascomycin
(pimecrolimus,
SDZ ASM 981)
Cyclic depsipeptide Streptomyces
tsukubaensis (bacteria)
Inhibition of
calcineurin by
complex with FK
binding proteins
Nephrotoxicity,
neurotoxicity,
higher risk for skin
cancer
Released: AdvagrafW,
ModigrafW, PrografW,
ProtopicW; ElidelW
[25]
Homophymines Cyclic depsipeptide Homophymia spp.
(marine sponge)
Antiproliferative,
mechanism
unknown
Cytotoxic In vitro [83,84]
Geodiamolides H Cyclic depsipeptide Geodia corticostylifera
(marine sponge)
Disorganization of
actin filaments
Cytotoxic In vitro [85]
Hymenistatin I Cyclic octapeptide Hymeniucidon spp.
(marine sponge)
Modulation of the
IL2 cell response
(comparable with
rapamycin)
Not reported In vivo studies [86]
Jasplakinolide Cyclic depsipeptide Jaspis splendens (marine
sponge)
Actin stabilization,
induces actin
polymerization
Cytotoxic In vitro [87]
Sirolimus (rapamycin),
everolimus (and
derivatives)
Cyclic depsipeptide Streptomyces
hygroscopius (bacteria)
Inhibition of mTOR Hyperlipidemia,
thrombocyopenia
Released: RapamuneW,
CerticanW, ZortressW,
AfinitorW
[26,88]
Ribosomally synthesized and post-translationally modified peptides
Charybdotoxin Venom peptide Leiurus quinquestriatus
hebraeus (scorpion)
Potassium channel
blocker
Less selective
blocker
In vitro [35]
Curcacycline B Orbitide Jatropha curcas (plant) PPIase inhbitior Cytotoxic,
carcinogenic
In vitro [89]
Cycloleonurinin Orbitide Leonurus heterophyllus
(plant)
Not known Not reported In vitro [31,89]
Cyclolinopeptide A/B Orbitide Linum usitatissimum
(plant)
CYPA binding and
calcineurin inhibition
Antiapoptotic,
nontoxic in vivo
In vivo studies on rats
and mice as immune
suppressive compound
and as stimulatory
compound with
metathroxate; toxicity
studies in mice and rats
[31,51,53]
Iberiotoxin Venom peptide Buthus tamulus
(scorpion)
Potassium channel
blocker
Blocker of several
BK channels
In vitro and in vivo (rats) [18]
Kalata B1 Cyclotide Oldenlandia affinis
(plant)
Antiproliferative,
IL2-dependent
mechanism
No cytotoxicity
observed at active
dose, cell cycle
arrest
In vitro and in vivo [69,70]
Kaliotoxin Venom peptide Androctonus
mauretanicus (scorpion)
Potassium channel
blocker
Not tested In vitro [90]
Magatoxin Venom peptide Centruroides
margaritatus (scorpion)
Potassium channel
blocker
Cytotoxic up to
20 mM
In vivo (guinea pigs) [91,92]
OSK-1 (alpha-KTx3.7) Venom peptide Orthochirus
scrobiculosus (scorpion)
Potassium channel
blocker
LD50 = 10 mg/kg
(mouse),
neurotoxic
In vitro and in vivo [93]
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FIGURE 1
Non-ribosomally synthesized immunosuppressive peptide compounds. The
structures of two of the most frequently used immunosuppressive peptide
drugs in the clinic, namely the cyclic undecapeptide cyclosporine A (a) and
the depsipeptide sirolimus (rapamycin) (b) are shown. Cyclosporine A has
many unique characteristics: it is a highly hydrophobic compound with seven
N-methylated amide nitrogens, these modifications are often reported for
non-ribosomal peptides from fungi and bacteria. The methylations also favor
cis-peptide confirmation and they reduce the number of hydrogen bonds to
their surrounding molecules. For example, it is a potent calcineurin blocker,
where it forms an inhibitory complex with cyclophilins and members of the
peptidyl-prolyl cis–trans-isomerase receptor family. The bacterial cyclic
depsipeptide sirolimus binds to other immunophilins (namely the FK506-
binding proteins) and this complex binds to mammaliam target of rapamycin
(mTOR) and inhibits its serine–threonine kinase activity. Another potent
648 www.drugdiscoverytoday.com
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Streptomyces hygroscopicus, and everolimus, a more hydrophilic
analog of sirolimus, also bind to FKBP-12; they are structurally
related to tacrolimus but do not affect calcineurin signaling.
Instead, they directly block mTOR signaling, which induces cell
cycle arrest [26,27]. Because mTOR is a pivotal protein kinase
involved in many physiological processes the list of side-effects
of sirolimus and everolimus is long, including leuko- and
thrombo-cytopenia, hypercholesterinemia, anorexia and gastro-
enterocolitis [27].
Didemnins are depsipeptides from the marine sponge Trididem-
num solidum. In particular, didemnin B (Fig. 1C) was characterized
for its immunosuppressive and antitumor activities [22]. Didem-
nin B inhibits lymphocyte activation at concentrations of 10 pg/
ml (IC50), which corresponds to a 100-fold increased potency
compared with CsA. However, didemnin B had no influence on
IL2 or IL4 cytokine levels; observations of a delayed cell cycle
progression led to suggestions about a nonspecific effect on the
basis of RNA and/or protein inhibition and cell toxicity rather than
a targeted effect as observed for CsA. A detailed study comparing
naive lymphocytes and lymphoblasts provided evidence that sev-
eral didemnins exhibited a cytotoxic, but also a targeted mode-of-
action [28]. More recently, target deconvolution studies revealed
that didemnin B binds to palmitoyl protein thioesterase 1 and
eukaryotic elongation factor 1a. It was found that the calmodulin/
Ca2+-dependent phosphorylation of the latter was inhibited com-
petitively, similar to that reported for CsA [29]. These cellular
targets might explain the reduced protein synthesis of cells by
didemnin B and give evidence for a target mechanism [28]. Uptake
of didemnin B by strongly proliferating cells was significantly
higher and therefore this compound appeared as an ideal drug
in cancer treatment or to suppress activation of the immune
system. But several clinical studies surprisingly failed during Phase
I or II because of unexpected in vivo toxicity in humans and also
because of a strong administration dependency caused by a very
short half-life [22]. Nevertheless, didemnins are very well investi-
gated and for human welfare they still possess an interesting
repertoire of antiproliferative and immunosuppressive peptide
drugs. In fact this was exemplified for the compound aplidin, a
didemnin-derived cyclic peptide that is in Phase II and Phase III
clinical trials for anticancer studies of solid and hematological
malignant neoplasm, T cell lymphoma, myelofibrosis and multi-
ple myeloma [22,30].
Ribosomally synthesized and post-translationally modified
peptides
Ribosomally synthesized and post-translationally modified small
peptides (RiPPs) occur in many taxa and are gene-encoded synthe-
sized as precursor proteins. These precursors consist of several
domains each with specific functions; detailed information about
RiPPs and their biosynthesis was recently reviewed [31,32]immunosuppressive depsipeptide analog is didemnin B (c), which has been
isolated from a marine tunicate (sea squirt). It shares its overall structure (i.e.
cyclic backbone, a cis-amide bond and a hydrophobic surface) with
cyclosporine A and sirolimus. However, it probably targets the eukaryotic
elongation factor 1A and palmitoyl thioesterase 1 to exert its antiproliferative
activity. Aplidin, a didemnin B derivative, is currently in Phase III clinical trials
and could be released onto the market within the next few years.
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FIGURE 2
Ribosomally synthesized immunosuppressive peptides. In contrast to small non-ribosomally synthesized peptides that were mainly isolated from microorganisms,
fungi and marine sources, there are a number of gene-encoded bioactive peptides with immunosuppressive activity from higher organisms, such as plants and
animals. They are all synthesized via a common mechanism from a larger precursor protein consisting of a signal peptide, an N-terminal leader sequence followed by a
core region and a short C-terminal recognition sequence (a). The precursor will be post-translationally modified to form and release the mature peptide from the core
region. The leader sequence and C-terminal recognition sequence are important for excision, cyclization and post-translational processing of the mature domain. The
N-terminal endoplasmic reticulum (ER) signal is important for cellular translocation to secretory compartments such as the ER [31]. Exemplarily, the structural cartoons
(stick-mode or ribbon cartoon) of four immunosuppressive gene-encoded peptides are shown (b–e). The primary structures are illustrated below the cartoon and
head-to tail cyclization of the backbone is indicated, where applicable. The cysteine residues are numbered with Roman numerals and the backbone loops labeled,
where applicable. The structure of the ShK toxin from the sea anemone Stichodactyla helianthus is presented (b). The cysteine connectivity is highlighted in yellow. The
peptide is a 35-mer with a molecular weight of 4061 Da. The secondary structure consists of two short a-helices between residues 14–19 and 21–24 and a pair of 310-
helices resembling turns from residue 9 to 13. The structure of the aKTX-type scorpion venom toxin Vm24 (c) from Vaejovis mexicanus smithi is shown and the four
disulfide bonds are highlighted in yellow. The C terminus of this peptide is amidated (as indicated by an asterisk). The molecular weight of this 36-mer peptide is
3864 Da. The secondary structure consists of a small a-helix between residues 13 and 16 and an extended triple-stranded antiparallel b-sheet. Cyclolinopeptide A (d)
from Linum usitatissimum is known as a promising immunosuppressive compound. The heptapeptide has a molecular mass of 1040 Da and it is shown in a ribbon
cartoon with backbone atoms in grey, oxygens in blue and nitrogens in red. The secondary structure is a b-turn and its X-Pro amide bond is in cis conformation. The
cyclotide kalata B1 (e) is illustrated as a ribbon cartoon. The 29-mer has a molecular mass of 2890 Da. The head-to-tail cyclized peptide is stabilized by its unique
cystine-knot motif. Characteristic secondary structure elements of cyclotides include a b-hairpin involving loop 4 and loop 5. A third strand within loop 1 is associated
with the hairpin to form a triple-stranded b-sheet as indicated. Several intramolecular hydrogen bonds further stabilize the topology of the peptide.
www.drugdiscoverytoday.com 649
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lational modifications (e.g. cyclization, oxidative folding, hydro-
lysis, ligations, phosphorylation) necessary for their biosynthesis.
The manifold of chemical modifications reported for RiPPs reflect
nature’s biosynthetic potential and the high diversity of RiPPs to
serve as peptide libraries for drug discovery.
Venom toxins. Venom toxins provide an enormous library of
natural products for drug development [21]. There is high variability
among all venom toxins isolated from sea anemones, snakes, scor-
pions, cone snails, jelly fish and other animals. Most of them are
linear peptides and, like the conopeptides and certain scorpion
venom peptides, are rich in cysteines to stabilize their active con-
formation [31]. The most common mode-of-action for many bioac-
tive venom toxins with clinical potential is the blockage of ion
channels [18]. Currently, there is one synthetic conopeptide on the
market, namely ziconotide (Prialt1) derived from the v-conotoxin
MVIIA of Conus magnus to treat patients with severe chronic pain
[19]. Nevertheless, the therapeutic application of ziconotide is
limited by its toxicity [33], but improvements in the administration
regime provided protection against severe side-effects [34].
Ion channels, often expressed by specific cell types, are generally
found to be promising targets for new drugs, on the basis of their
important influence on cell signaling, cell communication and
regulation of the cell membrane potential [35]. In particular,
calcium (Ca2+) and potassium (K+) ion channels play an important
part during T cell activation, and are therefore attractive for future
drug development [36]. After T cell stimulation, intracellular Ca2+
is released from the endoplasmic reticulum into the cytosol via
inositol-1,4,5-trisphosphate (IP3). Furthermore, Ca
2+ release-acti-
vated channels (CRAC) promote the influx of extracellular Ca2+
into the cytosol. This sustained elevated cytosolic Ca2+ concentra-
tion triggers IL2 gene expression. To maintain the membrane
potential of the activated T cell and to ensure constant influx of
Ca2+ ions during the activation period, which depends on a
homeostatic intramolecular ion level and membrane potential,
IKCa and Kv1.3 channels play an important part by pumping out
K+ [37,38]. Importantly, several of these ion channels are found to
be highly upregulated in T cells from patients with autoimmune
diseases such as multiple sclerosis. Therefore, a blockage of these
channels would be an efficient pharmacological strategy [39].
There are several reports of peptide-based potassium channel
blockers [40,41], but they often lack specificity as a result of the
fact that the heteromeric members of a channel family frequently
consist of the same subunits. The ShK-type K+-channel blocker
from the sea anemone Stichodactyla heliathus is a well-characterized
representative for a potential immunosuppressive venom toxin. In
comparison to other K+-channel blockers from scorpions, ShK is
different and, for example, lacks a b-sheet, which is replaced by
two a-helices instead [40] (Fig. 2b). ShK blocks the T cell specific
Kv1.3 channel with an IC50 of 16 pM, as well as the Kv1.1 channel
and several other ion channels with high affinities. Intriguingly,
the lack of specificity was demonstrated because the D-allo-ShK
was still able to block several K+ ion channels with high affinity
[40,42]. However, recently it was suggested that the D-ShK
analog has 50,000-fold lower affinity for the Kv1.3 channel
(IC50 = 22 mM) as compared with the L-ShK analog (IC50 = 250 pM)
[43]. The SAR for the 35-mer peptide was studied intensively and
several modifications (ShK-Dap22, ShK-amide or ShK-K-amide)650 www.drugdiscoverytoday.comenhanced its selectivity, IC50 and serum stability. The example
of the ShK-K-amide peptide demonstrates the high potential of
peptide engineering: the amide derivative had increased selectiv-
ity to block the Kv1.3 over the Kv1.1 potassium channels [41].
Owing to the general importance of peptide toxins for drug dis-
covery, toxin analogs were characterized extensively in vitro and in
vivo in mouse models for autoimmune diseases such as multiple
sclerosis, delayed-type hypersensitivity, rheumatoid arthritis and
for chronic-relapsing, as well as acute adoptive autoimmune ence-
phalomyelitis [40,44].
The K+-channel blocker Vm24 (a-KTx 23.1) which was recently
isolated from the venom of the Mexican scorpion Vaejovis mexicanus
smithi is a potent and selective Kv1.3-channel blocker (Kd = 0.5–
2.9 pM) with a 1500-fold higher affinity for Kv1.3 compared to ten
other channels (Fig. 2c) [45,46]. This promising lead peptide was
intensively studied with respect to its SAR revealing two pharma-
cophores, namely the variable residues before the a-helix at position
13–16 and the conserved C-terminal b-hairpin, which are crucial for
channel specificity and channel inhibition, respectively [45]. The
Kv1.3-channel inhibition leads to an antiproliferative effect on
activated T cells or, to be more precise, it induces an IL2R down-
regulation and a disturbance in Ca2þi mobilization. Furthermore, it
was shown that the proliferation of effector memory T cells was
reduced, whereas naive and central memory T cells sustained their
proliferation by a compensatory upregulation of the IKCa1 channel.
Treatment of mice with 10 mg/kg of the venom peptide did not
show any toxicity, suggesting little off-target effects [44,46]. The
immunosuppressive activity was confirmed in vivo, using a delayed-
type hypersensitivity autoimmune mouse model, demonstrating a
significant reduction of symptoms of disease compared with the
control group [45].
In summary, venom toxins are promising tools to inhibit spe-
cific ion channel families effectively with picomolar or nanomolar
affinities. However, low channel selectivity and insufficient serum
stability require future optimization. Many venom toxins interfere
with IL2 cytokine signaling and their molecular targets are differ-
ent to calcineurin inhibitors (e.g. CsA), which offers possibilities
for co-administration therapy. One big step toward the develop-
ment of suitable immunosuppressive drugs in the near future is to
engineer peptides with increased stability for maintaining or
improving oral administration properties and a promising tool
to achieve this is peptide cyclization.
Plant orbitides. Orbitides are ribosomally synthesized N-to-C
cyclized plant peptides with five to 12 amino acids lacking
cysteines. Their distribution within the plant kingdom as well
as their primary sequences are very heterogeneous and were
summarized by a recent review [31]. Several members of the
orbitide family (i.e. cyclolinopeptides, cycloleonurinins, hymenis-
tatins and curcacyclines) exhibit potential immunosuppressive
activity. For example, cyclolinopeptides A and B (Fig. 2d) were
characterized as T cell antiproliferative peptides comparable to the
well-known immunosuppressive agent CsA [47]. Many orbitides
bind to cyclophilin A (and other cyclophilins) and subsequently
inhibit calcineurin-dependent T cell activation. Cyclolinopeptide
A exhibits a tenfold lower affinity for calcineurin than CsA and was
found to be nontoxic [48–51]. Meanwhile, several cyclolinopep-
tide A analogs have been synthesized successfully to enhance their
bioactivity further [52,53].
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weak affinity to their molecular target calcineurin. Additionally,
several peptide drugs are already on the market targeting the same
cellular receptor and exhibiting similar modes-of-action. Never-
theless, this peptide family appears to be of interest as a result of
their absence of toxicity, hopefully promising a lack of unwanted
side-effects in future applications.
Plant cyclotides. Cyclotides are possibly the largest class of
gene-encoded cyclic peptides [54]. They were initially discovered
from the African plant Oldenlandia affinis (Rubiaceae) that has
been traditionally used to speed up labor and to avoid postpartum
complications [55]. Recently the molecular principle of this utero-
tonic activity was elucidated: the oxytocic cyclotide kalata B7 was
found to modulate the oxytocin and vasopressin V1a receptors,
members of the G-protein-coupled receptor family, inducing
strong contractility in human uterine smooth muscle cells [56,57].
Extensive screening efforts for the discovery of novel cyclotide-
containing plants has led to the identification of these peptides in
the plant families of Rubiaceae, Violaceae, Cucurbitaceae, Faba-
ceae, Solanaceae and Poaceae, summarized in [58]. Cyclotides are
approximately 30 amino acids in size and common structural
features of all cyclotides are the cyclic cystine-knot motif, two
short antiparallel b-sheets and a few conserved residues that are
important for structural stability, folding and enzymatic proces-
sing [59–61].
The biological function of cyclotides appears to be a defense
against herbivores, based on observations that cyclotides modu-
late the growth and development of several invertebrate animals,
such as insects [62,63], molluscs [64] and nematodes [65]. Besides,
cyclotides exhibit a range of bioactivities such as anti-HIV [66],
anticancer [67] and antibacterial [68], and they are capable of
inhibiting the proliferation of immune cells [69].
Kalata B1 (Fig. 2e) was identified as an active compound in a
herbal extract of O. affinis using a bioactivity-guided screening
protocol for cell proliferation inhibition of human peripheral blood
mononuclear cells. Interestingly, the antiproliferative activity was
not caused by cytotoxicity but the lymphocytes were kept in cell
cycle arrest [69]. Following the discovery of a dose-dependent
immunosuppressive activity of kalata B1, the cellular mechanisms
and structure–activity studies were performed. Several amino acid
mutants of the cyclotide kalata B1, including an all-D-cyclotide
enantiomer, were synthesized and analyzed, revealing that the
inherent immunosuppressive activity of cyclotides was com-
pound-specific, stereospecific and directly related to T cell biology.
The IL2 cytokine release and the expression of the high affinity
IL2R of activated T cells were significantly reduced upon treatment
with an active lysine mutant [T20K]kalata B1. The effect was
reversible upon exogenous administration of IL2 [70]. The cyclo-
tide [T20K]kalata B1 exhibited similar IL2-dependent inhibitory
effects compared to CsA, but it is clear that cyclotides suppress T
cell polyfunctionality and arrest the proliferation of immune-
competent cells through inhibiting IL2 biology at more than
one site. Furthermore, the effector cytokines IFNg and TNFa
had a reduced expression level upon [T20K]kalata B1 treatment
[70]. Using a different approach, myelin oligodendrocyte-glyco-
protein-derived peptide fragments were grafted onto a cyclotide
scaffold, which did not only improve their stability but one
engineered molecule displayed potent ability to prevent diseasedevelopment in a mouse model of experimental autoimmune
encephalomyelitis [71].
Cyclotides are frequently referred to as potential drug templates
for medicinal and therapeutic applications, taking advantage of
their unique three-dimensional topology [72], which makes them
remarkably stable against chemical, thermal or enzymatic degra-
dation compared with linear peptides or peptides missing a well-
defined three-dimensional conformation [73]. In particular, the
cyclotide framework is further stabilized by three disulfide bonds
and the resulting cystine-knot motif [72]. Hence they have been
extensively investigated in peptide-grafting applications (i.e. graft-
ing of bioactive amino acid sequences onto the cyclotide scaffold)
summarized in [72] and exemplified in [74]. For instance, this
resulted in the synthesis of an orally bioavailable and active
bradykinin B1 receptor antagonist for successful pain therapy in
mice [75]. Improvements in bioavailability after oral administra-
tion are certainly one of the most promising aspects for cyclic
peptides as therapeutic agents. Furthermore, cyclic peptides in
general are considered to have enhanced selectivity over their
linear counterparts by conferring conformational constraint
[76,77]. This represents the great market potential of cyclotides
as effective peptide-based and presumably orally bioavailable
drugs [78].
Concluding remarks
There are a few immunosuppressive peptide drugs already on the
market or in the clinic (e.g. cyclosporine, sirolimus, tacrolimus),
but lack of specificity causes severe or even life-threatening side-
effects. One key requirement for modern pharmaceuticals is a
specific mode-of-action with little or no side-effects in vivo. Addi-
tional important points are their stability, bioavailability and
efficacy. Owing to today’s knowledge and technology, scientists
have access to huge libraries of bioactive peptides, present in all
kingdoms of life around the world. Therefore, a major aim in this
field is to find novel natural peptides with highly specific immune
inhibitory or modulatory activity profiles. Some examples of such
promising future peptide drugs that were discussed in this review
include animal peptide toxins (e.g. ShK and Vm24) and circular
plant peptides (e.g. orbitides and cyclotides). Owing to natural
selection and evolutionary pressure, these natural peptides were
optimized for specific targets and functions (i.e. predator defense,
catching prey, intraspecies messenger), fine-tuned over millions of
years and, hence, offer great advantages in drug development over
synthetic-derived compounds [79]. In addition, peptides can easily
be engineered, functionalized and modified to enhance their
bioavailability, stability and specificity and efficiency. Lastly, lead
products can be produced on a large-scale by chemical synthesis or
by recombinant technologies to fulfill the manifold requirements
of the pharmaceutical industry [21]. In summary, these immuno-
suppressive peptides derived from natural sources could occupy a
niche of compounds in the molecular mass range between 500 and
5000 Da, which is currently lacking, to drive the field of peptide
pharmaceuticals ahead into a bright future [21].
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